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Abstract
Objective-To determine cardiac mani-
festations in primary Sjogren's syndrome
(SS).
Methods-Echocardiographic examination
was undertaken in 64 patients (62 women,
two men) with primary SS (54 definite
(DSS) and 10 probable (PSS)) who had
systemic symptoms. Twenty one healthy
women volunteers of similar age acted as
controls.
Results-Acute exudative pericarditis
occurred in only one patient. An echo-
genic pericardium was demonstrated in 21
patients (19 DSS, two PSS) (33%) who had
a previous symptom free pericarditis, but
in none of the controls. Pulmonary press-
ure was significantly greater in the
patients than in the controls (31 (SD 8)
mm Hg compared with 24 (7) mm Hg), but
there was no significant difference be-
tween the DSS and PSS groups. Left ven-
tricular (LV) systolic function was similar
in patients and controls. Twenty two
patients (20 DSS, two PSS) and one
control subject were excluded from LV
diastolic function evaluation because of
conditions likely to influence the
parameters. Of the remaining 42 patients
with SS (34 DSS, eight PSS), 21 (17 DSS,
four PSS) had impaired diastolic
function, confirmed by several diastolic
parameters. LV diastolic dysfunction and
echogenic pericardium occurred indepen-
dently of each other, and there was no
correlation between the occurrence of
these silent cardiac abnormalities and the
clinical and laboratory findings.
Conclusion-Obvious cardiac involve-
ment is rare in primary SS, but clinically
silent manifestations (symptom free peri-
carditis and LV diastolic dysfunction) are
common. The clinical and prognostic
significance ofthese changes cannot yet be
defined.
(Ann Rheum Dis 1996; 55: 450-454)
Among the systemic manifestations of primary
Sjogren's syndrome (SS), articular, lung,
kidney, vascular, and gastrointestinal involve-
ment are well known.'" In contrast, cardiac
manifestations are mentioned only sporadically
in the literature.4 5 9 10 This is somewhat sur-
prising, as the other autoimmune connective
tissue diseases (systemic lupus erythematosus
(SLE), progressive systemic sclerosis (PSSc),
and rheumatoid arthritis (RA)) are associated
with a wide range of cardiac disorders.1'
Because of the known pulmonary and vascular
involvement, and the presence of various auto-
antibodies in primary SS, it seems improbable
that these alterations do not affect the heart.
The aim of our study was to define evident
or silent cardiac manifestations in primary SS.
Patients and methods
Sixty four consecutive patients (62 women,
two men) with primary SS (according to the
EU preliminary criteria of classification of the
disease'2) who had systemic symptoms have
been examined during the period since 1992;
54 of them had definite (DSS) and 10 had
probable (PSS) primary SS. The mean age of
the 64 patients was 59 (SD 12) years (range
29-80 years) and the mean duration of their
disease was 14 (7) years (range 3-29 years).
Twenty one healthy women volunteers of
similar age (mean 56 (10) years; range 27-68
years) who had no clinical or laboratory signs
of an acute or chronic disease acted as
controls.
All patients and control subjects were
examined by echocardiography with Toshiba
SSH 65A and Ultramark 9HDI equipment,
using the recommendations of the American
Society of Echocardiography.'3 14 The cardio-
logist was aware of the clinical diagnosis. Left
ventricular (LV) end diastolic diameter
(EDD), end systolic diameter (ESD), end
diastolic volume (EDV), end systolic volume
(ESV), ejection fraction (EF), and left atrial
diameter were measured. Valve structures and
function were examined using the colour
coded and continuous wave Doppler method.
Pulmonary pressure was calculated from the
tricuspidal retrograde flow velocity. The peri-
cardium was evaluated visually using two
dimensional and M-mode views. An echogenic
thickened pericardium was defined as a linear
bright band of dense echoes behind the
relatively echo free space of the posterior LV
myocardium. The thickened pericardium
exhibited the same amplitude of motion as the
epicardium of the posterior LV wall. 13
On line analysis of the routine echocardio-
gram (LV systolic function parameters,
measurement of the estimated pulmonary
pressure, and evaluation of the echodensity of
the pericardium) was not blinded, but the
evaluation was performed independently by
two examiners.
Transmitral flow velocities were recorded by
pulsatile Doppler methods, with the sample
volume located at the tips of the mitral leaflets
from the apical four chamber view.'5 Peak early
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diastolic (E wave) and atrial contraction (A
wave) velocities were measured by averaging
five cardiac cycles to avoid ventilatory influ-
ence on LV filling dynamics. Velocity time
integrals of early (VIE) and atrial (VTIA)
filling were obtained by digitising the contours
of at least five velocity curves. The following
LV diastolic parameters were calculated in a
blind manner using the Microsoft Vega
Computer System (off line analysis):
peak early diastolic filling (E wave, peak E)
(cm/s)
peak late diastolic filling (A wave, peak A)
(cm/s)
E:A ratio
acceleration time of the E wave (AT) (cm/s2)
deceleration time of the E wave (DT) (cm/s2)
diastolic filling time (DFT) (ms)
velocity time integral of the E wave (VTIE)
(cm)
Table 1 Clinical manifestations andfindings in patients with primary Sj6gren's syndrome
(SS)
Manifestations and examinations Frequency ofoccurrence
DSS PSS Total
(n = 54) (n 10) (n = 64)
Articular 51 9 60
Arthralgia 8 3 11
Arthritis 43 6 49
Vascular 24 4 28
Vasculitis 8 0 8
Purpura 8 0 8
Raynaud's syndrome 18 4 22
Renal 13 4 17
Complete RTA 10*t 0 10
Incomplete RTA 3 4 7
Upper airway 37 8 45
Lower airway 20 4 24
Bronchitis 10 2 12
PFT: Obstructive signs 5 0 5
Restrictive signs 2 0 2
Obstructive + restrictive 0 0 0
Normal 1 1 2
ND 2t 1 3
Lung fibrosis (radiographic) 10 2 12
PFT: Obstructive signs 2 0 2
Restrictive signs 2 1 3
Obstructive + restrictive I§ 0 1
Normal 2 1 3
ND 3 0 3
Antibody positivity
SS-A 391 0 39
SS-B 171 0 17
SS-A and/or SS-B 411 0 41
DSS = Definite SS; PSS = probable SS; RTA = renal tubular acidosis; PFT = pulmonary function
test; ND = not done.
*Chronic tubulointerstitial nephritis histologically and renal stones in one patient; trenal stones
in one patient; t = interstitial pneumonitis in one patient; Shistologically proved recurring
lymphocytic interstitial pneumonitis; ¶not determined in one patient.
Table 2 Echocardiographic findings in patients with primary Sjogren's syndrome (SS)
(n = 64)
Echocardiographic finding Frequency ofoccumnce
DSS PSS DSS + PSS (%/,)
Moderately dilated left ventricle 3/54 1/10 4/64 6
Diffuse myocardial lesion 2/54 0/10 2/64 3
Segmental wall motion disturbance 1/54 0/10 1/64 2
Concentric left ventricular hypertrophy 7/54 0/10 7/64 11
Mitral insufficiency (more than grade I) 2/54 1/10 3/64 5
Aortic insufficiency (more than grade I) 1/54 1/10 2/64 3
Mitral prolapse 2/54 1/10 3/64 5
Asymmetric septal hypertrophy 1/54 0/10 1/64 2
Echogenic pericardium 19/54 2/10 21/64 33
Increased estimated pulmonary pressure 21/54 3/10 24/64 37
Abnormal LV diastolic function* 17/34 4/8 21/42*
DSS = Definite SS; PSS = probable SS; LV = left ventricular.
*22 (20 DSS and two PSS) of the 64 patients excluded from evaluation.
velocity time integral of the A wave (VTIA)
(cm)
total velocity time integral (VTItot) (cm)
VTIE:VTIA
LV filling fraction (FFlv) (%)
atrial filling fraction (FFa) (%)
heart rate (beats/min)
cardiac output (CO) (ml/min)
In addition to routine laboratory tests,
immunological variables were determined in all
patients with primary SS: antinuclear anti-
bodies, IgM rheumatoid factor, antibodies to
native DNA, SS-A, SS-B, Sm, and RNP, lupus
erythematosus cell phenomenon, circulating
immunocomplexes, complement C3 concen-
trations, and serum immunoglobulins.
STATISTICS
The data are expressed as mean (SD).
Statistical analysis was by Student's t test for
comparison of the systolic LV function be-
tween SS patients and controls, and by analysis
of variance for evaluation of LV diastolic
parameters. Statistical significance, established
by the x2 test, was defined as p < 0 05.
Results
Table 1 lists the clinical findings. Articular
involvement (arthritis and arthralgia) was the
most common systemic manifestation of SS in
our patients (94%), followed by, in order of
frequency, involvement of the upper airways
(70%; rhinitis, pharyngolaryngitis, and trache-
itis sicca), vascular changes (44%; vasculitis
13%, purpura 13%, and Raynaud's phenom-
enon 34%), lower airway disease (38%;
bronchitis sicca, interstitial pneumonitis, and
lung fibrosis), renal manifestations (27%; renal
tubular acidosis and chronic tubulointerstitial
nephritis), and acute exudative pericarditis
(one patient).
Table 2 and the figure show the abnor-
malities, other than the last, obviously cardiac,
manifestation listed above, that were revealed
by echocardiography. An echogenic peri-
cardium was observed in 21 (19 DSS and two
PSS) of the 64 SS patients, but even though
the pericardium was echogenic, there were no
clinical signs of pericardial constriction, and
the chest radiograph did not show pericardial
calcifications in these patients. There were no
pericardial changes in the control subjects.
Reproducibility of measurement of LV
parameters calculated by analysis of variance
was good: there were no statistically significant
differences between repeated measurements.
LV systolic parameters (EDD, ESD, EDV,
ESV, and EF) and left atrial diameter did not
differ between the SS patients and the controls,
but the estimated pulmonary pressure was signi-
ficantly greater in the SS group (without signifi-
cant differences between DSS and PSS patients)
than in the control subjects (31 (8) mm Hg
compared with 24 (7) mm Hg) (p < 0-05).
Because of factors influencing LV diastolic
function, 22 patients with SS (20 DSS, two
PSS) (17 older than 60 years, one with valvular
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heart disease, three with LV hypertrophy, one
with diabetes mellitus), and one 68 year old
control subject were excluded from evaluation
of diastolic function of the heart. The LV
diastolic function was examined in the
remaining 42 patients with SS (34 DSS and
eight PSS) and in 20 age matched controls
(table 3). Of the diastolic parameters, only the
E:A ratio (regarded as the principal Doppler
index) was significantly smaller in the 42
patients than in the control subjects (098 (0-2)
compared with 1-15 (0 3)) (p < 0.05). E:A was
abnormal (< 1) in 21 of the 42 patients with SS
(17 DSS and four PSS). In the 17 DSS
patients, besides the reduced E:A, the values of
other diastolic parameters (peak E, DFT,
VTIE, VTIE:VTLA, FFlv, and FFa) were also
abnormal, differing significantly from those in
control subjects. In the four patients with PSS
who had an abnormal E:A ratio, the values of
most of these diastolic variables also differed
from those in the controls, but significance was
not calculated because of the small numbers
(table 3). In the remaining 21 patients with SS
who had a normal E:A ratio (> 1), these
parameters were also normal, and their values
did not differ significantly from those in the
controls.
No correlation was found between the LV
diastolic function and the presence of an
echogenic pericardium. Both the LV diastolic
function and the morphology of the peri-
cardium were assessed in parallel in 34 DSS
and eight PSS patients. Of the 12 patients with
DSS who had an echogenic pericardium, five
(42%) had an abnormal and seven (58%) had
a normal LV diastolic function. Among the 22
patients with DSS who had a normal
pericardium, the LV diastolic function was
abnormal in 12 (55%) and normal in 10
(45%). Among the eight patients with PSS,
two had an echogenic pericardium without LV
diastolic dysfunction. Of the remaining six
patients with a normal pericardium, two had a
normal and four had an abnormal diastolic
function.
Comparison of the echocardiographic dias-
tolic parameters against the age of the patient,
duration of the disease, presence of different
clinical manifestations, and type of treatment
(non-steroidal anti-inflammatory drugs, chloro-
quine, or corticosteroid) did not reveal any
significant correlation.
The immunological data revealed that only
SS-B antibody positivity occurred more
commonly in the patients with DSS who had
an LV diastolic dysfunction (nine of 17) than
in those without a diastolic disturbance (three
of 16; in one patient SS-A and SS-B antibodies
were not measured). The pericardial charac-
teristics were not significantly correlated with
any of the clinical and laboratory findings.
M-mode echocardwograms ofpatzents with primary Sjogren's syndrome. A: Normal
pericardium ofa 39year old patient. B: Moderately echogenic pericardium ofa 38year old
patient. C: Markedly echogenic pericardium ofa 49year old patient. White arrow indicates
pericardium.
Discussion
Involvement of the heart is a common finding
in most connective tissue diseases, pericarditis
being mentioned most often in the literature."'
Clinical experience and the literature both
indicate that primary SS differs from SLE,
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Table 3 Left ventricular (LV) diastolic parameters in patients withprimary Sjogren's
syndrome (SS) and in normal control subjects
LVdiastolic parameters SS patients with E:A <1 Contols
DSS + PSS DSS PSS (n = 20)
(n = 21) (n = 17) (n = 4)
Age (yr) 50 (8) 48 (8) 54 (8) 55 (10)
peak E (cm/s) 42 (13)* 41 (10)* 46 (13) 58 (20)
peakA (cm/s) 58 (16) 60 (15) 50 (15) 53 (20)
E:A ratio 0-75 (0-15)* 0 70 (0-12)* 0 94 (0-13) 1-15 (0 3)
DT (cm/s2) 180 (59) 184 (58) 163 (59) 211 (59)
AT (cm/s2) 78 (30) 80 (31) 70 (31) 77 (22)
DFT(ms) 398(116)* 395(117)* 411 (117) 488(91)
VTItot (cm) 12 (4) 12 (4) 12 (5) 14 (5)
VTIE (cm) 5-4 (2.4)* 5-4 (2 3)* 5-4 (2-4) 8-1 (2-9)
VTIA (cm) 6-1 (2 2) 6-5 (2-1) 5-8 (2-3) 5-7 (2 3)
VTIE:VTIAratio 0-9 (0 5)* 0-9 (0-5)* 0 9 (0-5) 1-4 (0-6)
FFlv (%) 35 (7)* 32 (5)* 38 (8) 41 (8)
FFa (%) 52 (13)* 54 (12)* 46 (13) 40 (9)
HR (beats/min) 80 (13) 80 (11) 79 (13) 75 (12)
Values are mean (SD).
DSS = Definite SS; PSS = probable SS; peak E, peak A = peak early and late diastolic filling; DT,
AT = deceleration and acceleration times of the E wave; DFT = diastolic filling time; VTItot,
VTIa, VTIA = total, F wave, and A wave velocity integrals; FFlv, FFa = left ventricular and atrial
filling fractions; HR = heart rate.
*p < 0 05 compared with controls.
PSSc, and RA as regards cardiac manifes-
tations. The cardiac involvement in SS was
described in detail by Shearn in his mono-
graph, but the cases reported corresponded to
secondary SS, in most cases associated with
SLE.16 In comprehensive studies of the clinical
profile of primary SS, cardiac involvement is
not mentioned, or there is only reference to the
possibility of pericarditis.16 9 10 16 In contrast,
there is an obvious relationship between pri-
mary SS and congenital heart block, the most
important clinical manifestation of neonatal
lupus syndromel7 a model of passively
acquired autoimmunity in which maternal
antibodies to SS-A cross the placenta and
damage the fetal myocardium and the
conducting system.'8 19
One patient exhibiting acute exudative peri-
carditis was the inspiration for our prospective
evaluation of cardiac manifestations in primary
SS.
Echocardiography demonstrated an echo-
dense pericardium in 33% of our patients with
primary SS. We believe that such an echogenic
pericardium is a consequence of a symptom
free pericarditis, primarily associated with the
basic disease. An echogenic pericardium could
also suggest a pericardial constriction," but in
our patients there were no clinical or radio-
logical signs of this condition. Naturally, in
some subjects the echogenic pericardium
might be explained by an intercurrent virus
infection, but the proportion of the patients
affected appears too great for them all to be
consequences of simple infections. The in-
creased calculated pulmonary pressure ob-
served in about one third of our patients may
have been a result of diffuse interstitial lung
disease.
LV diastolic dysfunction is an important
cause of cardiac morbidity and appears to be
one of the earliest detectable abnormalities in
a number of disorders, for example hyper-
tension, diabetes mellitus, and ischaemic heart
disease.20 Abnormal diastolic performance has
been observed both in conjunction with and in
the absence of a systolic dysfunction. Among
the diastolic function parameters, the ratio E:A
is regarded as the principal Doppler index of
diastolic function, because it is the most
reproducible and is relatively independent of
the preload and afterload conditions.'5 E:A is
¢1 in a normal subject, and <1 in the event
of an impaired LV relaxation. A diastolic
relaxation impairment of the LV in connective
tissue disorders (SLE, RA, PSSc, and sero-
negative spondylarthritides) has been de-
scribed previously. 21
LV function was investigated by Comec et al
in a limited number of patients with primary
SS.22 They found an impairment of diastolic
relaxation in six patients aged 63 to 73 years.
In the elderly, however, a decreased E:A ratio
need by no means be considered pathological.
This was the reason why we originally excluded
these patients from the diastolic function
evaluation. In our examinations, a finding of
LV diastolic function impairment was also
common in patients with primary SS, in spite
of the fact that we excluded from the
evaluation any patient with a condition that
itself would influence the value of E:A. In
subjects with a diastolic dysfunction, not only
was E:A decreased, but other parameters (for
example the diastolic filling time) also reflected
the disturbance in relaxation. The mechanism
of this impaired LV relaxation remains un-
known. One explanation may be myocardial
Raynaud's phenomenon, described in patients
with PSSc,23 24 while a small intramyocardial
vessel or vasa vasorum vasculitis is also
possible, but could have been confirmed only
by myocardial biopsy. Although the positivity
to SS-B antibody that occurred only in DSS
was more frequent in patients with an LV
diastolic dysfunction than in those without
one, it cannot be concluded that this antibody
has a direct pathological role in the develop-
ment of this cardiac change.
As we could not establish any correlation
between the LV diastolic dysfunction and the
presence of the echogenic pericardium, it
seems likely that these cardiac abnormalities
can develop independently of each other in
primary SS. Though both silent cardiac abnor-
malities were common findings in our patients
with SS, without significant differences in
incidence between the DSS and PSS groups,
the differences between the data obtained in
the patients with SS and in the control subjects
might be slightly exaggerated, as our control
group might be healthier than the average
population.
In summary, it may be concluded that
obvious heart involvement is rare, but clinically
silent changes are common in primary SS.
Although the latter probably do not exert any
serious influence on the disease outcome, and
though at present their clinical significance
cannot be defined, they nevertheless form part
of the clinical picture of primary SS. For this
reason, further study of their prognostic signifi-
cance may be indicated.
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